Ian Tomlinson

Chair of Apollo Therapeutics

Start Codon and Stevenage Bioscience Catalyst

Dr Ian Tomlinson has experience of innovation in both the large and small company environment, along with 11 years spent in academia at the MRC Laboratory of Molecular Biology and as a fellow of Trinity College in Cambridge, UK. In 2000, together with Nobel Laureate Sir Greg Winter, he co-founded Domantis Limited to develop an entirely new class of drugs based on domain antibodies. Domantis was acquired by GSK in 2007 for $454M. He was at GSK for 9 years where he was SVP, Head of Biopharmaceuticals R&D and Head of Worldwide Business Development. Having left GSK in 2015, he now chairs a number of smaller companies, including the Stevenage Bioscience Catalyst and Apollo Therapeutics, both of which are facilitating the early stage development of a range of life sciences projects.